Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5717 chemoprophylaxis in PfSPZ challenge
NCT04250363Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cabamiquine in malaria (10 arms), sponsored by Merck KGaA. Primary endpoints: Number of Participants Over Time With Positive Parasitemia, Time to First Positive Parasitemia Based on qPCR and 3 more. Started Feb 2020; status: completed.
02
Drugs
cabamiquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04250363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250363.